AMPE : Summary for Ampio Pharmaceuticals, Inc. - Yahoo Finance

U.S. Markets closed

Ampio Pharmaceuticals, Inc. (AMPE)

NYSE MKT - NYSE MKT Delayed Price. Currency in USD
Add to watchlist
0.81-0.01 (-0.65%)
At close: 4:02PM EDT
People also watch
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous Close0.82
Bid0.00 x
Ask0.00 x
Day's Range0.81 - 0.84
52 Week Range0.59 - 4.32
Avg. Volume259,434
Market Cap46.5M
PE Ratio (TTM)-2.28
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • American City Business Journals3 days ago

    Colorado biotech's accountants express 'substantial doubt' about firm's future

    In a recent 10-K filing with the Securities and Exchange Commission, Douglas County-based Ampio (AMPE) said "a 'going concern' opinion could impair our ability to finance our operations through the sale of debt or equity securities or through bank financing. Ampio is developing Ampion, an anti-inflammatory drug designed to treat to severe pain associated with osteoarthritis of the knee , which company officials are excited about. In the history of the company, we have never been as close to realizing what we believe to be the full potential of Ampion, both from a regulatory perspective as well as commercial," said Michael Macaluso, chairman, and CEO, in a statement .

  • PR Newswire3 days ago

    Ampio Updates Intellectual Property and Regulatory Exclusivity Strategy to Support the Commercialization of Ampion™

    ENGLEWOOD, Colo., March 23, 2017 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) announces the issuance of China Patent No 102210852 B for the production of an active ingredient of Ampion™, which completes the intellectual property protection in China. Mr. Macaluso, Ampio's CEO, noted that "With the issuance of this patent, the Company's two-prong strategy to obtain comprehensive and overlapping Intellectual Property and Regulatory Exclusivity protection for a commercial launch of Ampion™, expected in 2018, is nearing completion.

  • PR Newswire4 days ago

    Update - Ampio Pharmaceuticals Provides Corporate Update

    ENGLEWOOD, Colo., March 22, 2017 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE), a leader in the development of Ampion™, a low molecular weight fraction of human serum albumin with anti-inflammatory properties, today announced that it is re-issuing its previous release that was made on March 20, 2017 to incorporate certain disclosures that are required under the NYSE MKT Company Guide Sections 401(h) and 610(b). Included below are these additional disclosures along with the previously disclosed update of corporate activities. As stated in a press release dated February 27, 2017, having recently concluded a successful series of meetings with the US Food and Drug Administration ("FDA"), Ampio is preparing to initiate what is anticipated to be the final pivotal trial of Ampion™ to treat the severe pain associated with Kellgren-Lawrence grade 4 osteoarthritis of the knee ("OAK").